Entinostat: a promising treatment option for patients with advanced breast cancer
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone hyperacetylation and transcriptional activation of specific genes, with subsequent inhibition of cell proliferation, terminal differentiation and apoptosis. This oral HDAC inhibitor has been evaluated in Phase I and II trials in patients with advanced malignancies, and is in general well tolerated. Entinostat does not currently have regulatory approval for clinical use; however promising preclinical and clinical data exist in hormone-resistant breast cancer. An ECOG-ACRIN Phase III registration study is ongoing in advanced breast cancer (E2112, NCT02115282) and aims to confirm the overall survival advantage observed with the combination of exemestane and entinostat/placebo in the Phase II setting (ENCORE301 trial). This article provides an overview of the chemistry, pharmacokinetics/pharmacodynamics and available clinical data for entinostat with a focus on advanced breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Entinostat, an oral HDAC inhibitor, induces protein lysine acetylation in preclinical models, which leads to downregulation of estrogen-independent growth factor signaling pathways and normalization of estrogen receptor levels.9,10”
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Deacetylase inhibition promotes the generation and function of regulatory T cells
Tao, R., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., et al. (2007) · Nature Medicine · doi:10.1038/nm1652 · Cited by 924
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Self-citation
Research works printed but not linked: 1
- 10.1016/S1470-2045(14)71159-3 · DOI · Paper page
Cited by
Items 101–150 of 150
Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
Garmpis, N., Damaskos, C., Garmpi, A., Valsami, S. I., & Dimitroulis, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00013-9 · Cited by 9
Lin, C., Liu, P., Shi, C., Qiu, L., Shang, D., Lu, Z., Tu, Z., & Liu, H. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12834 · Cited by 5
Jung, M., Nicholas, N. S., Grindrod, S. C., & Dritschilo, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306168 · Cited by 5
Enhancing progestin therapy via HDAC inhibitors in endometrial cancer.
Li, Y., Zhou, W., Li, L., Li, J. W., Li, T., Huang, C., Lazaro-Camp, V. J., Kavlashvili, T., Zhang, Y., Reyes, H., et al. (2022) · PubMed · Cited by 11
Replacement of the hydroxamic acid group in the selective HDAC8 inhibitor PCI-34051
Long, K. E., Close, D. A., Johnston, P. A., & Huryn, D. M. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129810 · Cited by 4
Omran, M. M., Vafaei, S., Alkhrait, S., Yang, Q., & Al-Hendy, A. A. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70626 · Cited by 5
“Despite the promising data, entinostat has not yet been approved for clinical use by any regulatory agency [25].”
InfluentialMaietta, I., Domínguez-Arístegui, P., Álvarez, I. G., Atanes, O. R., Fontán, E. M. G., Teijeira, S., González‐Fernández, Á., & Simón‐Vázquez, R. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126155 · Cited by 5
Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
Adehin, A., Kennedy, M. A., Soyinka, J. O., Alatise, O. I., Olasehinde, O. O., & Bolaji, O. O. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s266314 · Cited by 7
Epigenetic therapeutic strategies in pancreatic cancer
Orlacchio, A., Muzyka, S., & Gonda, T. A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2023.10.002 · Cited by 5
Wang, C., Lei, L., Yang, X., Li, Y., Zhang, J., Xu, Y., & Si, S. (2024) · Pharmaceuticals · doi:10.3390/ph17040425 · Cited by 6
“In [20]. contrast to TSC and trichosctatin A, the class I selective HDAC inhibitor entinostat only inhibited the activity of HDAC1, which is in agreement with its HDAC inhibition profile [20].”
ResultLi, J., Hu, C., Ye, Y., Wei, S., Zhu, W., Liang, J., Cai, J., Lin, Y., Peng, L., Yan, G., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1623211 · Cited by 4
Overcoming Endocrine Resistance in Breast Cancer
Ferrari, P., & Nicolini, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00029-6 · Cited by 4
Elbatrawy, O. R., Deeb, M. A. E., Hagras, M., Agili, F., Hegazy, M., El-Husseiny, A. A., Elkady, M. A., Eissa, I. H., & El-Kalyoubi, S. A. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0106 · Cited by 3
Targeting nuclear receptor corepressors for reversible male contraception
Hong, S.-H., Castro, G., Wang, D., Nofsinger, R. R., Kane, M. A., Folias, A. E., Atkins, A. R., Yu, R. T., Napoli, J. L., Sassone‐Corsi, P., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320129121 · Cited by 6
“Furthermore, given the long half - life of MS - 275 in humans, a once - a - week contraceptive pill is a possibility (34).”
BackgroundTang, D., Mao, Z., Chen, S., Su, M., Lan, S., Yan, R., Xiang, Q., Zhao, X., Zhang, J., & Wang, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04004-4 · Cited by 3
“MS275 has shown promising results, especially against advanced breast cancer [8] and colon cancer in vitro [9].”
Advances and challenges of estrogen receptor-targeted agents in breast cancer
Hu, J., Zhong, S., Sun, H., Liu, J., & Fang, W. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01583-9 · Cited by 5
Karki, R., Vitorino, F. N. D. L., Searfoss, R. M., Lempiäinen, J. K., Arrowsmith, C. H., & Garcia, B. A. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117289 · Cited by 3
Galindo-Alvarez, N. L., Mendoza-Figueroa, H. L., Rosales‐Hernández, M. C., Bakalara, N., & Correa‐Basurto, J. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210915100826 · Cited by 2
Sun, D., Zhang, H., & Zhang, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1185418 · Cited by 3
“Furthermore, as a synthetic benzamide derivative class I histone deacetylase inhibitor, Entinostat has been examined in Phase I and II studies and is typically well tolerated in patients with advanced malignancies (Connolly et al., 2017).”
BackgroundZhang, L. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14399 · Cited by 3
“It can downregulate the estrogen-independent growth factor signaling pathway and promote the normalization of estrogen receptor levels by inducing protein lysine acetylation.(9,10) Additionally, entinostat has been proven to successfully reverse letrozole resistance in mouse models.”
BackgroundPharmacologic progress in higher-risk MDS: an uphill battle
Mina, A. A., & Zeidan, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2644384 · Cited by 1
Decoding the Snail transcriptional network: its role in cancer progression and therapy
Parfenyev, S. E., Nazarov, A. N., Daks, A. A., Fedorova, O. A., Barlev, N. A., & Shuvalov, O. Y. (2026) · Biology Direct · doi:10.1186/s13062-026-00751-1 · Cited by 2
“It has an IC50 of 0.51 µM for HDAC1 and 1.7 µM for HDAC3 [172].”
InfluentialAlmolhim, H. (2026) · Viruses · doi:10.3390/v18060673 · Cited by 1
“[48].”
Antiaging drugs, candidates, and food supplements: the journey so far
Yodhaanjali, J. R., Surya, R., Sumukha, K. C., Harini, G., Deshpande, G., Chandan, S. A., & Achar, R. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90235-9.00016-1 · Cited by 1
Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors
Droste, A., & Schmidt, M. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.94 · Cited by 1
Therapeutic Targeting of the Regulators of Cancer Epigenomes
Al-Janabi, I. I. (2023) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v5i.128 · Cited by 1
McCabe, C. (2019) · Research@THEA
Marcos, I. C. (2019) · Gredos (University of Salamanca) · doi:10.14201/gredos.140375
Identification of potential drug candidates for the treatment of triple-negative breast cancer
Naorem, L. D., Muthaiyan, M., Bhattacharyya, I., Ampasala, D. R., & Venkatesan, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822009-2.00002-9
Epigenetic therapy in lung cancer
Conroy, M. R., O’Connor, Á., Bailey‐Whyte, M., & Dowling, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91367-6.00004-0
Alshawli, A. S., Ahmed, T. A., Ahmed, F., Haque, A., El‐Say, K. M., Omar, A. M., & Abu-Elmagd, M. M. (2024) · Journal of Nanotechnology · doi:10.1155/2024/8207090
Costa, A., Bozdağ, M., Renzi, G., Rani, B., Passani, M. B., Angeli, A., Provensi, G., Carta, F., & Supuran, C. T. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70020
Rizwan, A., Aqeel, A., & Farooqi, H. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00589-z · Cited by 2
“Compared to non-selective HDAC inhibitors, they are safer and more effective because it causes histone hyperacetylation, reactivates tumour suppressor genes, and encourage apoptosis (Connolly et al. 2017).”
Booth, S. W., Eyre, T. A., Whittaker, J. A., Campo, L., Wang, L. M., Soilleux, E. J., Royston, D. J., Rees, G., Kesavan, M., Hildyard, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15047655
Terri, M., Sandoval, P., Bontempi, G., Montaldo, C., Tomero‐Sanz, H., de Turris, V., Trionfetti, F., Pascual‐Antón, L., Clares, I., Battistelli, C., et al. (2024) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · doi:10.6084/m9.figshare.25045388
Cavallo, F., Troglio, F., Fagà, G., Fancelli, D., Shyti, R., Trattaro, S., Zanella, M., D’Agostino, G., Hughes, J. M., Cera, M. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257785
Cavallo, F., Troglio, F., Fagà, G., Fancelli, D., Shyti, R., Trattaro, S., Zanella, M., D’Agostino, G., Hughes, J. M., Cera, M. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257791
Cavallo, F., Troglio, F., Fagà, G., Fancelli, D., Shyti, R., Trattaro, S., Zanella, M., D’Agostino, G., Hughes, J. M., Cera, M. R., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257788
卢尚辉, Liang, Y., Li, L., LIAO, S., Zou, Y., Yang, C., & Ouyang, D. (2024) · Figshare · doi:10.6084/m9.figshare.26657203
Reddy, Y., Bhat, V. G., Kumar, M. V., Das, I., & Babitha, K. S. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00868-0 · Cited by 1
Li, S., Xu, Y., Dong, J., Qiu, Y., Yang, Z. L., Gao, X., Gao, J., 冯章英, Wang, C., & Wang, M. (2026) · RSC Advances · doi:10.1039/d6ra03621j
Johnson, K., Lim, J. J., WU, W., Tu, N., & Zhang, S. X. (2026) · Research Square · doi:10.21203/rs.3.rs-9890379/v1
“The first approach involved Entinostat, a class I histone deacetylase (HDAC) inhibitor with well-documented immunomodulatory properties (33).”
Elgammal, W. E., Halawa, A. H., Turky, A., El‐Shershaby, M. H., Abdallah, A. E., & Alesawy, M. S. (2026) · New Journal of Chemistry · doi:10.1039/d6nj01766e
Aichouna, R., Saidi, K. M., Layoul, I., Stiti, M. Z., Habila, T., Harrouche, K., Apohan, E., Kılıç, A., Küçükbay, H., & Khelili, S. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147273
Lucaciu, R. L., Hangan, A. C., Oprean, L. S., & Procopciuc, L. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198619 · Cited by 1
BindingDB (2025) · UC San Diego · doi:10.7270/q2xs612h
BindingDB (2024) · UC San Diego · doi:10.7270/q2p55sv5
Metadata
- Authors
- Connolly, R. M., Rudek, M. A., & Piekarz, R.
- Affiliations
- Sidney Kimmel Comprehensive Cancer Center,Johns Hopkins School of Medicine, Baltimore, MD, USA
- Johns Hopkins University (US)
- National Institutes of Health (US)
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2017-03-09
- Volume
- 13
- Issue
- 13
- Pages
- 1137-1148
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- PMC
- PMC5618943
- OpenAlex
- W2591958823
- Cited by
- 148
- References
- 66
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 16 · 2021: 19 · 2020: 15 · 2019: 14 · 2018: 7 · 2017: 3
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Celgene
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- entinostat, histone deacetylase inhibitors, advanced breast cancer, hormone-resistant breast cancer, histone hyperacetylation, benzamide derivatives, pharmacokinetics, pharmacodynamics, anticancer drug development
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Female, Humans, Neoplasm Staging, Pyridines, Apoptosis, Epigenesis, Genetic, Cell Line, Tumor, Cell Proliferation, Histone Deacetylase Inhibitors, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.